Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Prospective, Placebo-controlled Trial to Assess the Immunogenicity, Safety, and Tolerability of a Coronavirus Vaccine in Healthy Volunteers Aged 18 to 60 Years

NCT05156723 is registered in ClinicalTrials.gov with St. Petersburg Research Institute of Vaccines and Sera as lead sponsor.

NCT NCT05156723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05156723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Prospective, Placebo-controlled Trial to Assess the Immunogenicity, Safety, and Tolerability of a Coronavirus Vaccine in Healthy Volunteers Aged 18 to 60 Years
Lead sponsor
St. Petersburg Research Institute of Vaccines and Sera
Phase
Phase 1/2
Overall status
Completed
Start date
July 19, 2021
Completion date
December 31, 2022
Enrollment
155 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infections, covid-19, immunologic factors, respiratory tract infections